These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 32248249)
1. Prescription medicines with potential for foetal harm: dispensing before and during pregnancy in New Zealand, 2005-2015. Donald S; Sharples K; Barson D; Horsburgh S; Parkin L Eur J Clin Pharmacol; 2020 Jun; 76(6):887-896. PubMed ID: 32248249 [TBL] [Abstract][Full Text] [Related]
2. Patterns of prescription medicine dispensing before and during pregnancy in New Zealand, 2005-2015. Donald S; Sharples K; Barson D; Horsburgh S; Parkin L PLoS One; 2020; 15(6):e0234153. PubMed ID: 32484824 [TBL] [Abstract][Full Text] [Related]
3. Utilisation of teratogenic medicines before and during pregnancy in Australian women. Raichand S; Pearson SA; Zoega H; Buckley NA; Havard A Aust N Z J Obstet Gynaecol; 2020 Apr; 60(2):218-224. PubMed ID: 31397495 [TBL] [Abstract][Full Text] [Related]
4. Drugs associated with teratogenic mechanisms. Part I: dispensing rates among pregnant women in the Netherlands, 1998-2009. van Gelder MM; Bos JH; Roeleveld N; de Jong-van den Berg LT Hum Reprod; 2014 Jan; 29(1):161-7. PubMed ID: 24105826 [TBL] [Abstract][Full Text] [Related]
5. Use of prescription medicines in Australian women of child-bearing age. Gadzhanova S; Roughead E BMC Pharmacol Toxicol; 2015 Dec; 16():33. PubMed ID: 26643036 [TBL] [Abstract][Full Text] [Related]
6. Concurrent use of hormonal long-acting reversible contraception by women of reproductive age dispensed teratogenic medications, Australia, 2013-2021: a retrospective cohort study. Grzeskowiak LE; Moore V; Hall K; Ilomäki J; Schoenaker D; Lovegrove E; Mazza D; Black KI; Kennedy DS; Davies MJ; Rumbold A Med J Aust; 2024 Oct; 221(7):367-373. PubMed ID: 39285147 [TBL] [Abstract][Full Text] [Related]
7. Dispensing of potentially teratogenic drugs before conception and during pregnancy: a population-based study. Zomerdijk IM; Ruiter R; Houweling LM; Herings RM; Straus SM; Stricker BH BJOG; 2015 Jul; 122(8):1119-29. PubMed ID: 25316196 [TBL] [Abstract][Full Text] [Related]
8. Generation of a pregnancy cohort for medicine utilisation and medicine safety studies in New Zealand. Donald S; Barson D; Horsburgh S; Sharples K; Parkin L Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1335-1343. PubMed ID: 30394649 [TBL] [Abstract][Full Text] [Related]
9. Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies. Sarayani A; Albogami Y; Thai TN; Smolinski NE; Patel P; Wang Y; Nduaguba S; Rasmussen SA; Winterstein AG Am J Obstet Gynecol; 2022 Aug; 227(2):263.e1-263.e38. PubMed ID: 35032444 [TBL] [Abstract][Full Text] [Related]
10. Perinatal psychotropic dispensing: A descriptive population-based study in New Zealand. Broughton LC; Hughes-Medlicott N; Zeng J; Smith A Asia Pac Psychiatry; 2023 Jun; 15(2-3):e12539. PubMed ID: 37321961 [TBL] [Abstract][Full Text] [Related]
11. Antidepressant dispensing before, during, and after pregnancy in New Zealand, 2005-2014. Donald S; Sharples K; Barson D; Horsburgh S; Parkin L Aust N Z J Obstet Gynaecol; 2021 Dec; 61(6):837-845. PubMed ID: 33908042 [TBL] [Abstract][Full Text] [Related]
12. Pharmacovigilance in pregnancy using population-based linked datasets. Colvin L; Slack-Smith L; Stanley FJ; Bower C Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):211-25. PubMed ID: 19173342 [TBL] [Abstract][Full Text] [Related]
13. Variation in the use of medicines by ethnicity during 2006/07 in New Zealand: a preliminary analysis. Metcalfe S; Laking G; Arnold J N Z Med J; 2013 Oct; 126(1384):14-41. PubMed ID: 24162628 [TBL] [Abstract][Full Text] [Related]
14. Use of privacy-preserving record linkage to examine the dispensing of pharmaceutical benefits scheme medicines to pregnant women in Western Australia. Kelty E; Hansen M; Randall S; Gration D; Baynam G; Preen DB Pharmacoepidemiol Drug Saf; 2024 Jun; 33(6):e5845. PubMed ID: 38825961 [TBL] [Abstract][Full Text] [Related]
15. Dispensing of Potentially Harmful Prescription Drugs in 1.8 Million Pregnant Women in France: A Nationwide Study Based on Two Risk Classification Systems. Blotière PO; Damase-Michel C; Weill A; Maura G Drug Saf; 2021 Dec; 44(12):1323-1339. PubMed ID: 34613596 [TBL] [Abstract][Full Text] [Related]
16. Provision of potentially teratogenic medications to female veterans of childbearing age. Schwarz EB; Longo LS; Zhao X; Stone RA; Cunningham F; Good CB Med Care; 2010 Sep; 48(9):834-42. PubMed ID: 20706159 [TBL] [Abstract][Full Text] [Related]
17. The Most Commonly Dispensed Prescription Medications Among Pregnant Women Enrolled in the U.S. Medicaid Program. Palmsten K; Hernández-Díaz S; Chambers CD; Mogun H; Lai S; Gilmer TP; Huybrechts KF Obstet Gynecol; 2015 Sep; 126(3):465-473. PubMed ID: 26244530 [TBL] [Abstract][Full Text] [Related]
18. Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001-2006). Daw JR; Mintzes B; Law MR; Hanley GE; Morgan SG Clin Ther; 2012 Jan; 34(1):239-249.e2. PubMed ID: 22169049 [TBL] [Abstract][Full Text] [Related]
19. Concomitant use of contraceptives and potentially teratogenic medicinal products--results from a study using pharmacy dispensing data in the Netherlands. Ruiter R; Teichert M; Straus SM; Stricker BH; Visser LE Reprod Sci; 2012 Sep; 19(9):987-94. PubMed ID: 22527986 [TBL] [Abstract][Full Text] [Related]
20. Perceptions by pregnant and childbearing-age women in southern Brazil towards teratogenic risk from medicines and radiotherapy. Pons Eda S; Pizzol Tda S; Knauth DR Cad Saude Publica; 2014 Sep; 30(9):1965-76. PubMed ID: 25317525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]